Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Boston Scientific Corporation (NYSE:BSX)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Boston Scientific stock on May 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.
• Sold $15,001 – $50,000 in shares of Workday (NASDAQ:WDAY) on 5/29/2026.

Boston Scientific Stock Up 0.4%

Boston Scientific stock opened at $48.92 on Wednesday. Boston Scientific Corporation has a fifty-two week low of $47.17 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm has a 50 day moving average price of $57.28 and a 200 day moving average price of $75.83. The company has a market capitalization of $72.71 billion, a PE ratio of 20.47, a price-to-earnings-growth ratio of 0.91 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter last year, the firm earned $0.75 EPS. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on BSX shares. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a report on Thursday, April 23rd. Raymond James Financial restated an “outperform” rating and issued a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Jefferies Financial Group dropped their price target on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Daiwa Securities Group downgraded shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, Truist Financial dropped their price target on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.92.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors have recently modified their holdings of the business. Murphy & Mullick Capital Management Corp lifted its position in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter worth $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Finally, Colonial Trust Co SC lifted its position in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other news, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig acquired 3,580 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 9,800 shares of company stock valued at $554,012. Insiders own 0.34% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.